May 27, 2019
Hisamitsu Pharmaceutical has delivered encouraging results from its re-designed Japan PIII trial on its investigational cancer pain drug HP-3150, setting the table for its planned filing within this fiscal year ending February 2020. The study looked into the efficacy and...read more